Mylan, Upjohn unveil branding for Viatris
Mylan and Upjohn, a division of Pfizer, today unveiled the logo and branding for Viatris, the new company that will be formed from their combination.
The companies said that the new logo and branding are designed to reflect Viatris' guiding principles that will redefine the healthcare landscape through its capability, commitment and vision to address evolving healthcare needs. Viatris' platform will provide a unique Global Healthcare Gateway that will offer partners ready access to more markets and patients worldwide.
Viatris (pronounced 'viǝ-trīs) is Latin for "three paths," and the logo visually captures the company's commitment to access, leadership and partnership. The "three paths" work together in harmony and encircle a simplified globe to illustrate the company's core purpose of empowering people worldwide to live healthier at every stage of life.
"Viatris will be focused on creating a more sustainable healthcare journey for patients worldwide while delivering value to all stakeholders for years to come. The Viatris branding reflects our drive to address the world's emerging healthcare needs with passion and compassion. It also highlights our goal to chart a new course focused on improving patient outcomes by expanding access to medicine, providing leadership through innovative solutions and building best-in-class partnerships, said future Viatris executive chairman and current Mylan executive chairman Robert Coury.
Coury added, “We also will offer all partners ready access to more markets and the ability to reach more patients around the world through the company's new and unique Global Healthcare Gateway, which leverages Viatris' unmatched global infrastructure to connect people around the world to the high-quality medicines and services they need, making Viatris a true Partner of Choice."
Future Viatris CEO and current Upjohn Group president Michael Goettler said, "Our new branding exemplifies that we are building a new kind of company designed for where the healthcare industry is going. Viatris will have the global reach, commercial offerings and capabilities, as well as the scientific, medical, regulatory, legal and intellectual property expertise necessary to ensure more patients can get the care they need to live healthier at every stage of life. Viatris will be uniquely positioned to help patients access the medicines they need regardless of their geography or circumstance."
The transaction, which was overwhelmingly approved by Mylan shareholders at Mylan's Extraordinary General Meeting of Shareholders on June 30, 2020, and is expected to close in the fourth quarter of 2020.